April is officially recognized as Rosacea Awareness Month, a time dedicated to educating the public, raising awareness, and reducing the stigma surrounding this often misunderstood chronic skin condition. For over 30 years, this month-long observance has helped to shine a light on rosacea, a condition that affects more than 16 million Americans and an estimated 400 million people worldwide. Despite its widespread prevalence, rosacea remains an issue that many are unaware of, and it is frequently misdiagnosed or misunderstood.

Rosacea is a complex and multifaceted condition, characterized by redness, visible blood vessels, and sometimes acne-like breakouts. It can impact individuals in varying degrees, from mild flushing to severe inflammatory symptoms. The condition can affect not just the skin but also a person’s emotional well-being, as it is often associated with visible facial redness, which can lead to feelings of self-consciousness and embarrassment.

Interestingly, while rosacea is so common, there is only one official consensus statement on the condition, which is provided by the American Acne and Rosacea Society (AARS). This statement offers guidance on the diagnosis, treatment, and management of rosacea, and is considered a key resource for healthcare providers. It serves as the definitive document on the subject, despite the fact that rosacea can manifest in different ways and affect patients in diverse forms.

In addition to the AARS consensus statement, the last five years have witnessed important advancements in the treatment of rosacea. Three new medications have been approved by the FDA, providing patients with more options for managing the condition. These developments are significant, as they reflect the ongoing commitment to improving rosacea treatment options and enhancing the quality of life for those affected.

The main focus of this article will be to highlight the AARS consensus statement and delve into the recent updates from the FDA regarding rosacea treatments in recognition of Rosacea Awareness Month 2025. By understanding these updates, we can better inform those living with rosacea and ensure they have the latest information on how to effectively manage their condition.

Part 1 - Current Rosacea Guidelines/Consensus Statements

To start, here is a listing of the current rosacea guidelines/consensus statements:

Part 2 - Recent FDA Approvals

Below, are the recent medications and therapies recently approved by the FDA that we anticipate being incorporated into future US guidelines:

  • ZILXI (minocycline)
    • Journey Medical
    • FDA approved in June 2020 for rosacea
    • ZILXI is a tetracycline-class drug indicated for the treatment of inflammatory lesions of rosacea in adults.

  • EPSOLAY (benzoyl peroxide) 
    • Galderma Laboratories
    • FDA approved in April 2022
    • EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults.

  • EMROSI (minocycline hydrochloride)
    • Journey Medical
    • FDA approved in November 2024 for rosacea
    • EMROSI is a tetracycline-class drug indicated to treat inflammatory lesions (papules and pustules) of rosacea in adults.

Thank you for taking the time to review the current rosacea guidelines/consensus, as well as the recent major changes and FDA approvals that have recently occurred. We value your feedback and would like to hear your suggestions for future topics to be covered in our guideline series. Please feel free to contact us with any ideas or questions you may have.

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, All rights reserved.